These were as follows: amikacin (Bristol-Myers Squibb, Syracuse, NY, USA); amoxicillin, ampicillin, azlocillin, cefotaxime, cefuroxime, cycloserine, chloramphenicol, gentamicin, norfloxacin, rifampicin, sulfamethoxazole and tobramycin (Sigma, Steinheim, Germany); ceftazidime and aciclovir (GlaxoSmithKline, Greenford, UK); ciprofloxacin and moxifloxacin (Bayer AG, Wuppertal, Germany); flucloxacillin (GlaxoSmithKline, Welwyn Garden City, UK); 5-flucytosine and ganciclovir (Roche, Welwyn Garden City, UK); linezolid (Pharmacia, Kalamazoo, MI, USA); meropenem (AstraZeneca, Södertälje, Sweden); netilmicin (Schering-Plough, Kenilworth, NJ, USA); ofloxacin (Aventis Pharma, West Malling, UK); penicillin-G A rapid high-performance liquid chromatography (HPLC) assay for the detection of linezolid in human serum was developed. The method used a Hypersil 5ODS stationary phase. The mobile phase was 1% ortho-phosphoric acid, 30% methanol, 2 g/L heptane sulphonic acid, pH 5. UV absorbance detection was used (λ max 254 nm). Samples were prepared by mixing with acetonitrile and an injection volume of 20 µL was used. The inter-and intra-day assay reproducibility were assessed. Assay linearity, specificity and accuracy were investigated. The detection limit and recovery of linezolid from serum were determined. In addition, the stability of linezolid, stored under a variety of conditions, was assessed. The retention time of linezolid was c. 6.5 min. The intra-and inter-day reproducibility was good and the assay was linear across the therapeutic range. Serum recovery was c. 100% at all concentrations tested. The detection limit was 0.1 mg/L and the assay was accurate. The assay was specific as there was no significant interference with the linezolid peak. Linezolid was demonstrated to be stable. This rapid assay is ideal for busy clinical laboratories with basic HPLC equipment.
Introduction
Linezolid (PNU-100766), an oxazolidinone, is a new antibacterial agent recently licensed in Europe and the USA. It has a unique mode of action, inhibiting protein synthesis early in translation. 1 As a result, cross-resistance with other antimicrobial agents is believed to be unlikely. The drug has a broad spectrum of activity against Gram-positive organisms including methicillin-resistant Staphylococcus aureus (MRSA), penicillin-resistant pneumococci and vancomycin-resistant Enterococcus faecalis and Enterococcus faecium. [2] [3] [4] [5] Linezolid is available in both iv and oral formulations. Early clinical data indicate that linezolid 600 mg bd is as effective as vancomycin 1 g bd for the treatment of MRSA and hospital-acquired pneumonia. 6 A linezolid peak concentration of 18 mg/L (1-2 h post-dose) and a minimal serum concentration of 4 mg/L after 625 mg bd can be expected.
The stationary phase was Hypersil 5ODS, 10 cm ϫ 4.6 mm (Waters Corporation, Milford, MA, USA).
The mobile phase was 1% ortho-phosphoric acid, 30% methanol, 2 g/L heptane sulphonic acid, adjusted to pH 5 by the addition of 10 M sodium hydroxide. The pump flow rate was 1.0 mL/min. UV absorbance detection was used ( max 254 nm). A Gina 50 autosampler was used (Dionex, Macclesfield, UK) and the integrator was a Trilab 2000 (Trivector, Sandy, UK).
Sample preparation
Samples were prepared by mixing aliquots (50:50) of the specimen with acetonitrile. The samples were mixed, allowed to rest at ambient temperature for 10 min and centrifuged at 5000g for 5 min. Twenty microlitres of the supernatant was injected.
Reproducibility
Serum specimens containing 5, 15 and 30 mg/L linezolid were assayed (n ϭ 3). Mean peak heights Ϯ S.D. (x Ϯ S.D.) and percentage coefficients of variation (% CV) were calculated [(S.D./mean) ϫ 100] over a single day to assess intra-day reproducibility and on days 1, 2, 6 and 7 of the evaluation to assess inter-day reproducibility.
Linezolid stability
All stability determinations (apart from the freeze-thaw investigations) were carried out using 0.4, 25 and 45 mg/L linezolid serum samples. Initially, the drug stability was assessed over a 24 h period after acetonitrile sample preparation. Linezolid stability after storage at 4ЊC and at room temperature was determined by assay (n ϭ 3) on day 7 of the study. For these stability investigations, the calculated concentration on day 1 was compared with that measured on day 7, and the percentage original calculated [(day 2 or 7 concentration/day 1 concentration) ϫ 100]. Linezolid was also subjected to two heat treatment cycles (56ЊC for 45 min; serum samples from high-risk groups are virally inactivated in this way). Drug stability was determined by assay (n ϭ 6) of samples before heat treatment and re-assay (n ϭ 3) after the first cycle. After cooling to room temperature, the samples were subjected to a further cycle and the sample assayed again (n ϭ 3). Calculated concentrations before heat treatment were compared with those after each cycle and the percentage of the original concentration calculated. Linezolid stability was assessed after two freeze-thaw cycles. This was determined by assay (n ϭ 3) of a serum linezolid 8 mg/L sample thawed after storage at Ϫ70ЊC. The sample was returned to the freezer, frozen, thawed and assayed (n ϭ 3) once more. The percentage weighed-in concentration was calculated after each cycle. The long-term stability of linezolid was assessed by the assay (n ϭ 3) of 0.4, 25 and 50 mg/L linezolid serum samples after storage at Ϫ70ЊC for 1 year. The measured concentrations were compared with those of the weighedin samples.
Linearity
Linearity was determined with serum samples spiked with 0.0, 0.5, 1, 5, 10, 15, 20 and 30 mg/L linezolid. The samples were assayed (n ϭ 3) and the mean peak height was calculated and plotted against sample concentration. Linearity was investigated via regression analysis.
Recovery
This was investigated with serum and aqueous samples spiked with 0.0, 0.5, 1, 5, 10, 15, 25 and 30 mg/L linezolid. The samples were assayed (n ϭ 6) and peak heights measured. The mean peak height was plotted against linezolid concentration and the percentage recovery calculated [(mean aqueous peak height/mean serum peak height) ϫ 100].
Lowest limit of quantification
The lowest limit of quantification is defined as the concentration equivalent of a peak approximately three times the height of the baseline noise. A linezolid serum sample was prepared to approximately this concentration. The sample was assayed (n ϭ 3) and peak height Ϯ S.D. and % CV calculated.
Specificity
The assay was evaluated for any possible interference from other antimicrobial, antifungal and antiviral drugs that may be co-administered with linezolid. The antimicrobial agents for assessment were prepared to contain clinically appropriate concentrations. After sample preparation, The method was also assessed for any interference from unknown endogenous compounds in patient sera. Twelve linezolid-free serum samples (sent to our laboratory for antibiotic assay) were selected at random. The samples were prepared and assayed.
Accuracy using single point calibration
The accuracy of the method was evaluated by the preparation and assay (n ϭ 6) of serum samples spiked to contain 2.5, 8 and 18 mg/L linezolid using a 12 mg/L serum calibrator.
Results

Assay validation
The separated linezolid peak is shown in Figure 1 . Assay reproducibility was: intra-day Ͻ6%; inter-day Ͻ12.5% (Table) . The correlation between drug concentration and peak height was good for both aqueous and serum samples across the concentration range (r ϭ 0.9999 for both; Figure 2 ). Linezolid recovery from serum approached 100% at all concentrations tested. The lowest limit of quantification was calculated to be 0.1 mg/L. The accuracy, expressed as the percentage error [100 ϫ (measured concentration -target concentration)/target concentration] was 4.0 for the 2.5 mg/L sample, 1.3 for the 8 mg/L sample and 0.0 for the 18 mg/L sample. There was no interference from 23 commonly used antimicrobial agents or from any unknown compound present in linezolid-free patient sera. Benzyl-penicillin eluted close to linezolid. However, this was not considered to be significant since benzyl-penicillin 20 mg/L resulted in a peak equivalent to linezolid 0.4 mg/L. Furthermore, benzyl-penicillin can be removed by -lactamase.
Drug stability
Linezolid was stable in serum, after sample preparation with acetonitrile, at room temperature over a 24 h period ( Figure 3) . The drug was stable in serum alone for at least 7 days at both room temperature and 4ЊC.
The final mean drug concentrations were all c. 100% of the original, apart from 0.4 mg/L kept at 4ЊC for which the final mean drug concentration was only 86.2% of the original. This was a somewhat aberrant result, particularly since the 0.4 mg/L serum sample kept at room temperature 607 was stable over the same time period. No drug degradation was found after two heat treatment cycles. The linezolid concentrations were c. 100% of the original concentrations after the first and second cycles. There was little drug loss after two freeze-thaw cycles. The linezolid concentration was 96.4% of the original concentration after the first cycle and 91.7% after the second. Linezolid was stable after storage for 1 year at Ϫ70ЊC; the measured drug concentrations were c. 100% of the weighed-in concentrations.
Discussion
We have demonstrated linezolid to be stable in serum in the short term (р7 days) at room temperature and at 4ЊC. This means that samples can be transported without having to use ice or liquid CO 2 . The drug is also stable for up to 24 h after treatment with acetonitrile. This means that samples can be prepared and assayed in a batch within a 24 h time period without loss of antibiotic content. Linezolid was also stable after heat treatment. The drug was subjected to two such cycles. Serum samples from high-risk patients may therefore be heat treated before forwarding to a reference laboratory and again upon receipt. Linezolid was stable after storage at Ϫ70ЊC for up to 1 year and after two freeze-thaw cycles. Batches of samples can, therefore, be stored in the long term at Ϫ70ЊC. The assay is reproducible, accurate and linear across the concentration range. Linezolid was fully recoverable from serum. The lowest limit of detection (0.1 mg/L) is somewhat lower than the MICs for control organisms (0.5-4 mg/L; Linezolid Technical Information, unpublished). The only published HPLC method for linezolid has been validated for dog, mouse, rabbit and rat plasma. 8 This method uses a time-consuming and complicated sample preparation step using solid-phase extraction. With our method, sample preparation is quick and simple, and up to 150 assays can be performed before there is a change in chromatographic performance. With a retention time of only 6.5 min, it is ideal for the processing of clinical samples. 
